Last reviewed · How we verify
IMP761
At a glance
| Generic name | IMP761 |
|---|---|
| Sponsor | Immutep S.A.S. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMP761 CI brief — competitive landscape report
- IMP761 updates RSS · CI watch RSS
- Immutep S.A.S. portfolio CI